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INTRODUCTION 
The introduction of general anesthetics into clinical practice over 
150 years ago stands as one of the seminal innovations of medicine. This 
single discovery facilitated the development of modern surgery and 
spawned the speciality of anaesthesiology. 
General anesthesia can broadly be defined as a drug-induced 
reversible depression of the central nervous system resulting in the loss of 
response to and perception of all external stimuli. General anesthesia is a 
dynamic balance between the level of hypnosis, analgesia, and stimulation. 
It is usually defined as a triad of amnesia, analgesia, and muscle 
relaxation. 
Inhalation anesthetics are the most common drugs used for the provision 
of general anesthesia. Adding only a fraction of a volatile anesthetic to the 
inspired oxygen results in a state of unconsciousness and amnesia. When 
combined with intravenous adjuvants, opioids and benzodiazepines, a 
balanced anesthetic technique is achieved that results in analgesia, further 
sedation or hypnosis, and amnesia. The popularity of the inhaled 
anesthetics for surgical procedures is because of their ease of 
administration and the ability to reliably monitor their effects with both 
clinical signs and end-tidal concentrations.  
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Inhaled volatile anaesthetics remain the most widely used drugs for 
maintenance of general anesthesia because of their predictable 
intraoperative and recovery characteristics. Management of 
haemodynamic stability and early recovery is the most important part of a 
standardized balanced technique. 
Rapid induction and recovery may lead to faster operating room turnover 
times, shorter recovery room stays, and earlier discharges to home. 
  Over the last 15 years, there has been an explosive growth in the 
trend to provide cost-effective care in the practice of medicine. 
Ambulatory surgery is an increasingly important part of that trend. 
Ambulatory surgery continues to grow and thrive such that the vast 
majority (65–70%) of all surgical procedures is performed on an outpatient 
basis. Expeditious recovery and shorter hospital stays are necessary to 
improve efficiency of an ambulatory facility and reduce health care costs. 
One of the major factors that determine the speed of recovery from 
anesthesia is the choice of anesthetic technique. Although local and 
regional anesthesia techniques are increasingly used in the ambulatory 
setting because they allow a more rapid recovery , general anesthesia is 
still the most common anesthetic technique. An ideal general anesthetic 
technique should provide smooth and rapid induction, optimal operating 
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conditions, and rapid recovery with minimal or no side effects. It is also 
beneficial if the anesthetic technique allows for fast tracking (i.e, 
transferring patients directly from the operating room to the phase II unit, 
thus bypassing the postanesthesia care unit [PACU]). 
Inhaled anaesthetics allow rapid emergence from anaesthesia 
because of easy titrability with inherent neuromuscular blocking effects 
that make them more suitable for ambulatory anaesthesia. The availability 
of less soluble inhalation anaesthetics such as sevoflurane and desflurane 
made us rethink about the selection of volatile anaesthetics for outpatient 
surgical procedures. Given the low blood: gas partition coefficient of 
sevoflurane and desflurane, faster emergence from anaesthesia is expected 
compared to traditional inhalation anaesthetics.   
The purpose of this study was to compare the sevoflurane and 
desflurane in terms of hemodynamic, emergence and recovery 
characteristics. 
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AIM OF THE STUDY 
This study was undertaken with the aim of prospectively comparing 
the hemodynamic, emergence and recovery characteristics of sevoflurane 
with those of desflurane in general anesthesia. 
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HISTORY 
Inhalational anesthetics date back to the dawn of anesthesia. 
Humphry Davy first observed the analgesic effects of  Nitrous oxide 
long ago in 1800, and called it as “ laughing gas”. Horace Wells in 1844 
described the use of nitrous oxide to facilitate the extraction of a tooth.  
Henry Hill Hickman, in 1824 demonstrated that anesthesia could 
be induced and surgical procedures carried out using carbon dioxide. He 
was the one who introduced the concept of anesthesia using an inhaled 
substance. The first recorded general anesthetic administered in humans 
was in 1842, when both C W Long and W Clarke successfully induced 
anesthesia using diethyl ether. 
The first successful public demonstration of anesthesia was in 1846, 
when W T G Morton successfully induced anesthesia using Ether on 16 
October at Massachusetts General Hospital. 
Discovered in 1831, the use of chloroform in anesthesia is linked 
to James Young Simpson, who, in a wide-ranging study of organic 
compounds, found chloroform's efficacy on 4th  November 1847. Its use 
spread quickly and gained royal approval in 1853 when John Snow gave 
it to Queen Victoria during the birth of Prince Leopold. 
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These two agents, along with nitrous oxide, remained the mainstays 
of anesthesia along with nitrous oxide for the next 80 years, until the 
introduction of cyclopropane in 1930 by Lucas and Henderson in 
Toronto. Other agents used around this time included divinyl ether, 
trichloroethylene, and ethyl chloride. Lehmann first described the general 
anesthetic effects of trichloroethylene in 1911. 
In 1932, Booth and Bixby observed that the greatest potential for 
non-combustible anesthetic agents lay with organic fluoride compounds, 
because the substitution of fluoride for other halogens reduces the boiling 
point, increases the stability, and generally reduces the toxicity of gases. 
Fluroxene, the first fluorine-containing anesthetic agent introduced in 
1950. 
First of the truly modern anesthetics, Halothane was first 
synthesised in 1951 by C W Suckling and was first introduced into 
clinical practice by Michael Johnstone in Manchester in 1956. Research 
into fluorinated compounds continued and has led to the production of all 
the modern anesthetic agents.  
Methoxyflurane introduced in 1960, was soon withdrawn from the 
market due to its nephrotoxic potential. Fluroxene is explosive in 
concentrations greater than 3%. 
7 
 
Enflurane was produced by R C Terrell of Ohio Medical Products 
and it was first used in man in 1966. It is a halogenated methyl ethyl ether. 
Isoflurane was first produced in 1968 by Dr R C Terrell. It is a structural 
isomer of enflurane, a halogenated methyl ethyl ether. 
Sevoflurane was first synthesised in the late 1960s at Baxter-
Travenol laboratories by R F Wallin and co-workers. The first recorded 
use in humans was in 1981.  
Desflurane was produced by Dr Ross Terrell and it was approved 
for clinical use in 1992. It is a fluorinated methyl ethyl ether. 
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INHALATIONAL ANESTHETICS 
MECHANISM OF ACTION: 
Inhaled anesthetics act in different ways at the level of the central 
nervous system. They may disrupt normal synaptic transmission by 
interfering with the release of neurotransmitters from presynaptic nerve 
terminal (enhance or depress excitatory or inhibitory transmission), by 
altering the re-uptake of neurotransmitters, by changing the binding of 
neurotransmitters to the post-synaptic receptor sites, or by influencing the 
ionic conductance change that follows activation of the post-synaptic 
receptor by neurotransmitters. Both, pre-synaptic and postsynaptic effects 
have been found. 
Direct interaction with the neuronal plasma membrane is very likely, 
but indirect action via production of a second messenger also remains 
possible. The high correlation between lipid solubility and anesthetic 
potency suggests that the inhalational anesthetics have a hydrophobic site 
of action. Inhalation agents may bind to both membrane lipids and 
proteins. It is at this time not clear, which of the different theories is most 
likely to be the main mechanism of action of inhalation anesthetics. 
                The affinity of anesthetic drugs for lipids was soon recognized, 
which led to early lipid-based hypothesis of anesthetic action. The 
  
MECHANISM OF ACTION 
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formulation of the Meyer-Overton correlation at the end of the 19th 
century was a watershed event, introducing a rigorous scientific approach 
into anesthesia research. Meyer concluded in 1899 that “All chemically 
indifferent substances that are soluble in fat are anesthetics … their 
relative potency as anesthetics will depend on their affinity to fat on the 
one hand and water on the other hand, that is, on the fat/water partition 
coefficient,” a conclusion that was reached independently by Overton. 
             The Meyer-Overton theory describes the correlation between lipid 
solubility of inhaled anesthetics and Minimun Alveolar Concentration and 
suggests that anesthesia occurs when a sufficient number of inhalation 
anesthetic molecules dissolve in the lipid cell membrane. The Meyer-
Overton rule postulates that the number of molecules dissolved in the lipid 
cell membrane and not the type of inhalation agent causes anesthesia. 
Combinations of different inhaled anesthetics may have additive effects at 
the level of the cell membrane. 
However, the Meyer-Overton theory does not describe why 
anesthesia occurs. Mullins expanded the Meyer-Overton rule by adding 
the so-called Critical Volume Hypothesis. He stated that the absorption of 
anesthetic molecules could expand the volume of a hydrophobic region 
within the cell membrane and subsequently distort channels necessary for 
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sodium ion flux and the development of action potentials necessary for 
synaptic transmission. The fact that anesthesia occurs with significant 
increase in volume of hydrophobic solvents and is reversible by 
compressing the volume of the expanded hydrophobic region of the cell 
membrane supports Mullins Critical Volume Hypothesis. 
  A focus on protein targets gained momentum in the 1980s owing 
largely to the work of Franks and Lieb, who convincingly demonstrated 
that protein targets are also compatible with the Meyer-Overton correlation 
and proposed that anesthetics competitively antagonize protein function. 
The enantiomeric selectivity of several anesthetics further strengthened the 
case for specific binding sites on proteins, such as ion channels, as the 
principal molecular targets of inhaled anesthetics. Today, there is 
widespread (but not universal) acceptance of the notion that critical 
signalling proteins (e.g., ion channels and receptors) are the relevant 
molecular targets of anesthetic action even though the mechanisms of their 
modulation by anesthetics are debated. 
MOLECULAR TARGETS OF INHALED ANESTHETICS: 
Ion channels have emerged as the most promising molecular targets 
for inhaled anesthetics. Neurotransmitter-gated ion channels, in particular 
GABAA, glycine, and NMDA-type glutamate receptors, are leading 
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candidates owing to their appropriate CNS distributions, essential 
physiologic roles in inhibitory and excitatory synaptic transmission, and 
sensitivities to clinically relevant concentrations of anesthetics. Other ion 
channels that are sensitive to inhaled anesthetics include the HCN 
(hyperpolarization-activated cyclic nucleotide-gated) family of channels 
that give rise to pacemaker currents and regulate dendritic excitability, 
two-pore domain (K2P) “leak” K+ channels that maintain resting membrane 
potential in many cells, and voltage-gated Na+ and Ca2+ channels. 
Inhaled anesthetics can be divided into two classes based on their 
distinct pharmacologic properties. The first class is the potent inhaled 
(volatile) anesthetics, which exhibit positive modulation of GABAA 
receptors, also produce significant, anesthesia-compatible effects on a 
number of other receptors or channels, including enhancement of 
inhibitory glycine receptors, inhibition of excitatory NMDA and neuronal 
nicotinic acetylcholine receptors, activation of K2P channels, and inhibition 
of presynaptic Na+ channels. Intravenous anesthetics such as propofol and 
etomidate represent more potent and specific positive modulators of 
GABAA receptors. The second class is the gaseous inhaled anesthetics, 
which include cyclopropane, nitrous oxide, and xenon. These anesthetics 
are inactive at GABAA receptors, but block NMDA receptors and activate 
12 
 
certain K2P channels at clinical concentrations. The intravenous anesthetic 
ketamine is a more potent and specific blocker of NMDA receptors. 
  Each of the mentioned theories describes a unitary theory of 
narcosis. They all concentrate more or less on an unique site of action for 
inhaled anesthetics. The true mechanism of action of volatile anesthetics 
may be a combination of two or more such theories described as multisite 
action hypothesis. 
MINIMUM ALVEOLAR CONCENTRATION ( MAC ): 
Anesthetic potency of volatile anesthetics is measured by the 
minimum alveolar concentration (MAC). This value represents the 
minimum percent alveolar concentration of an anesthetic (at one 
atmosphere) that prevents movement in 50 percent of the subjects in 
response to supramaximal stimulus. A variety of noxious stimuli have 
been used to provoke response. For determination of MAC in humans, the 
usual stimulus used is surgical skin incision. In daily practice, MAC must 
be exceeded by a factor of 1.3 in order to assure sufficient surgical 
anesthesia for most of our patients. 1.3 times MAC will prevent movement 
in about 95 percent of the patients because MAC is ED50. The idea of 
measuring MAC is that after a short period of equilibration the alveolar 
concentration of the gas equals the blood concentration and a little later 
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equals the brain concentration. According to Dalton’s law of partial 
pressure of gases, partial pressure can be substituted for concentration. 
Therefore , it represents after a short time the partial pressure of the 
anesthetic in the central nervous system (CNS) and it is therefore the most 
useful index of anesthetic potency. 
            MAC is age-dependent, being lowest in newborns, reaching a peak 
in infants, and then decreasing progressively with increasing age. MAC 
values for inhaled anesthetics are additive, which means that the addition 
of nitrous oxide will decrease the MAC of another volatile anesthetic. The 
MAC can also be reduced following administration of opioids. Inhalation 
anesthetics alone are not able to suppress hemodynamic responses to 
painful stimuli nor does MAC for skin incision predict the concentrations 
of inhalation anesthetics necessary to avoid the motor responses to other 
painful stimuli such as endotracheal intubation. As a rule of thumb, the 
addition of every one percent of alveolar nitrous oxide to another 
inhalation anesthetic will cause decrease in the MAC of that gas about one 
percent. Increases in MAC result from hyperthermia and hypernatremia. 
Decreases in MAC can result from hypothermia, hyponatremia, 
pregnancy, hypotension, and drugs such as lithium, lidocaine, opioids, 
and α2 agonists. 
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MAC creates a unifying principle of anesthetic depth for the inhaled 
anesthetics. Although each inhaled anesthetic has some pharmacologic 
peculiarities, in general they have parallel dose-response curves across 
drugs (e.g., isoflurane versus sevoflurane versus desflurane). 
MAC- it is the end-tidal concentration of the inhaled anesthetic at one 
atmospheric pressure required to prevent movement  in response to a 
noxious stimulus in 50% of subjects. ( example - MAC of nitrous oxide- 
104%, sevoflurane-1.8 to 2 % ). 
MAC AWAKE - it is the end-tidal concentration associated with response 
to verbal stimulation in 50% of subjects. As a fraction of MAC, the MAC-
awake of nitrous oxide (65% of MAC) exceeds that of desflurane, 
isoflurane, and sevoflurane (approximately 33% of MAC). 
MAC BAR - the end-tidal concentration of the inhaled anesthetic that 
blocks adrenergic response in 50% of subjects. 
UPTAKE AND DISTRIBUTION OF INHALED ANESTHETICS: 
A series of partial pressure gradients, beginning at the vaporizer of 
the anesthetic machine, continuing in the anesthetic breathing circuit, the 
alveolar tree, blood, and tissue will ensure the forward movement of the 
gas. The principal objective of that movement is to achieve equal partial 
pressures on both sides of each single barrier. The alveolar partial 
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pressure governs the partial pressure of the anesthetic in all body tissues; 
they all will ultimately equal the alveolar partial pressure of the gas. After 
a short period of equilibration, the alveolar partial pressure of the gas 
equals the brain partial pressure. It is therefore most important to 
understand how to influence the alveolar partial pressure. It can be raised 
by increasing minute ventilation, setting a higher concentration on the 
vaporizer dial and by using a non-rebreathing circuit. Two special effects 
increasing the amount of gas in the alveoli have to be mentioned 
separately. 
The concentration effect: 
Describes how the concentration of the gas in the remaining alveolar 
volume can increase after some of the gas has been transferred into the 
blood.  
The second gas effect: 
  Usually refers to nitrous oxide combined with an inhalation agent. 
Because nitrous oxide is not soluble in blood, its rapid absorption from 
alveoli causes an abrupt rise in the alveolar concentration of the other 
inhaled anesthetic. 
All the above mentioned factors influence the inflow of gas into the 
alveoli. 
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Solubility, cardiac output, and the alveolar to arterial anesthetic 
gradient represent outflow factors. Inflow factors minus outflow factors 
equal alveolar partial pressure of the gas. 
Solubility:  
It describes the affinity of the gas for a medium such as blood or fat 
tissue. The blood/gas partition coefficient describes how the gas will 
partition itself between the two phases after equilibrium has been reached. 
Isoflurane for example has a blood/gas partition coefficient of 1.4. This 
means that if the gas is in equilibrium the concentration in blood will be 
1.4 times higher than the concentration in the alveoli. 
 A higher blood gas partition coefficient means  
- A higher uptake of the gas into the blood  
- Slower induction time. 
-  It takes longer until the equilibrium with the brain partial pressure of 
the gas is reached. 
Cardiac Output: 
A higher cardiac output removes more volatile anesthetic from the 
alveoli and therefore lowers the alveolar partial pressure of the gas. The 
agent might be faster distributed within the body but the partial pressure in 
the arterial blood is lower. It will take longer for the gas to reach an 
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equilibrium between the alveoli and the brain. Therefore, a high cardiac 
output prolongs induction time. 
Alveolar to venous partial pressure difference: 
The alveolar to arterial partial pressure difference reflects tissue 
uptake of the inhaled anesthetic. A large difference is caused by increased 
uptake of the gas during the induction phase. This facilitates the diffusion 
of the gas from the alveoli into the blood. 
Next we have to discuss the transfer of the gas from the arterial 
blood into the tissues such as the brain. It will depend on perfusion and 
solubility of the gas into different tissues. The brain/blood coefficient 
describes how the gas will partition itself between the two phases after 
equilibrium has been reached. Isoflurane for example has a brain/blood 
coefficient of 1.6 meaning that if the gas is in equilibrium the 
concentration in the brain will be 1.6 times higher than the concentration 
in the blood. All inhalation anesthetics have high fat/blood partition 
coefficients. This means that most of the gas will bind to fatty tissue as 
time goes by. The partial pressure of the gas in fatty tissue will rise very 
slowly. Inhalation anesthetics stored in such tissue in obese patients may 
delay awakening at the end of anesthesia. The body tissues have been 
divided into groups according to the level of perfusion and blood flow. 
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¾ Vessel rich group     - VRG     brain, heart, kidney, liver 
¾ Muscle group           - MG       muscle and skin 
¾ Fat group                  - FG        large capacity / minimal flow 
¾ Vessel poor group    - VPG     bone, cartilage and connective tissue 
 
Tissue Group Characteristics 
 
Group 
Vessel Rich Muscle Fat Vessel Poor
Percentage of body mass 10 50 20 20 
Perfusion as a percentage of 
cardiac output 
75 19 6 0 
 
Metabolism and elimination of inhaled anesthetics: 
                           Metabolism is important for two reasons. First, 
intermediatory metabolites, end metabolites, or breakdown products from 
exposure to carbon dioxide absorbents may be toxic to the kidneys, liver, 
or reproductive organs. Second, the degree of metabolism may influence 
the rate of decrease in the alveolar partial pressure at the conclusion of the 
anesthetic. 
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Assessment of the magnitude of metabolism of the inhaled anesthetics is 
by 
       (a) Measurement of metabolites or 
       (b) Comparison of the total amount of anesthetic recovered in the 
exhaled gases with the amount taken up during administration. (Mass 
balance). 
Determinants of metabolism: 
The magnitude of metabolism of inhaled anesthetics is determined by the  
                     -   Chemical structure 
                     -   Hepatic enzyme activity 
                     -   Blood concentration of the anesthetic 
                     -   Genetic factors 
Chemical Structure - the ether bond and carbon-halogen bond are the 
sites in the anesthetic molecule most susceptible to oxidative metabolism. 
Hepatic Enzyme Activity - the activity of hepatic cytochrome P-450 
enzymes responsive for metabolism of volatile anesthetics may be 
increased by a variety of drugs, including the anesthetics themselves. 
There is evidence in patients that brief (1hour) exposures during surgical 
stimulation increase hepatic microsomal enzyme activity independent of 
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the anesthetic drug or technique used. Conversely, surgery lasting more 
than 4 hours can lead to depressed microsomal enzyme activity. 
Blood Concentration - the fraction of anesthetic that is metabolised on 
passing through the liver is influenced by the blood concentration of the 
anesthetic. For example, a 1 MAC concentration saturates hepatic enzymes 
and decreases the fraction of anesthetic that is removed during a single 
passage through the liver. Conversely, subanesthetic concentrations (< 0.1 
MAC) undergo extensive metabolism on passage through the liver. 
Inhaled anesthetics that are not highly soluble in blood and tissues tend to 
be exhaled rapidly via the lungs at the conclusion of an anesthetic. As a 
result, less drug is available to pass through the liver continually at low 
blood concentrations conductive to metabolism. This is reflected in the 
magnitude of metabolism of these drugs. 
Genetic factors - overall, genetic factors appear to be the most important 
determinant of drug-metabolising enzyme activity. In this regard, humans 
are active metabolizers of drugs compared to lower animal species such as 
the rat. 
             Induction and recovery from anesthesia with volatile anesthetics 
differ somewhat from each other. On induction all tissue partial pressures 
are zero. During recovery, different tissues in the body have a different 
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partial pressure of the inhaled anesthetic. Therefore, recovery is not as 
controllable as induction of anesthesia. In addition, increasing minute 
ventilation and concentration of the inspired anesthetic mixture can 
significantly accelerate induction. Increasing minute ventilation with high 
inspiratory oxygen concentration will increase the gradient of the inhaled 
anesthetic between pulmonary venous blood and the alveolar space and 
therefore increase the elimination of the gas. In summary, elimination of a 
volatile anesthetic depends  on ventilation, cardiac output, and solubility of 
the gas in blood and tissue. 
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PHARMACOLOGY OF DRUGS 
DESFLURANE 
Desflurane was produced by Dr Ross Terrell. It was approved for 
clinical use in 1992. 
Physical properties: 
¾ Desflurane is a fluorinated methyl ethyl ether. 
¾ Has a pungent odour, irritating and unpleasant to inhale. 
¾ Molecular weight: 168.04 Dalton  
¾ Boiling point: 22.8 ºC 
¾ Saturated vapour pressure: 664 mmHg 
¾ Blood-gas solubility: 0.42 
¾ Minimum alveolar concentration: 6% 
Chemical structure: 2,2,2-trifluoro-1-fluoroethyl-difluoromethyl ether 
Pharmacokinetics: 
Desflurane has the lowest blood-gas solubility of all the volatile 
anesthetics. Thus, it results in faster induction and faster recovery. Yasuda 
et al. have shown that equilibration of the FA/FI ( fraction of alveolar to 
the inspired concentration) ratio of desflurane is higher than that of either 
isoflurane or halothane. At 30 min the FA/FI ratio of desflurane was 0.9 
compared to 0.73 for isoflurane and 0.58 for halothane. 
  
 
DESFLURANE: MOLECULAR STRUCTURE 
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Partition Coefficients of desflurane at 37ºC: 
Blood-Gas       : 0.42 
Brain-blood     : 1.3 
Liver-Blood    : 1.4 
Kidney-Blood : 1.0 
Muscle-Blood  : 2.0 
Fat-Blood        : 27 
The distribution of desflurane follows a five-compartment model 
which, it has been postulated, may be as follows – the lungs, the vessel-
rich group of organs, muscle, fat around the vessel rich organs, and finally, 
peripheral fat. 
The elimination of desflurane is almost exclusively through the lungs, with 
metabolism by the liver estimated to be less than 0.02%. 
Pharmacodynamics: 
Central nervous system: 
Cerebral blood flow - desflurane has two effects on cerebral blood flow. 
Cerebral vasodilatation causes increase in cerebral blood flow while 
decrease in cerebral metabolic rate causes decrease in cerebral blood flow. 
Of these, vasodilatation predominates and there is global increase in 
cerebral blood flow. 
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Cerebral metabolic rate - desflurane causes a reduction in cerebral 
metabolic rate. 
Intracranial pressure - drug induced vasodilatation tends to raise the 
intracranial pressure. This effect is not offset by hypocapnia. 
The more rapid recovery associated with desflurane anesthesia may offer a 
small advantage in patients undergoing prolonged neurosurgical 
procedures. 
Respiratory system: 
Desflurane is irritating to the airway. So, it is unsuitable for 
inhalation induction. Concentrations of desflurane more than 6% cause 
coughing, breath-holding, and laryngospasm both in adults and children. 
It is a potent respiratory depressant. It causes a dose-dependent decrease in 
tidal volume and an increase in respiratory rate, with an overall reduction 
in minute alveolar ventilation. Paco2 increases and the ventilatory 
response to carbon dioxide is reduced. 
Desflurane causes concentration-dependent bronchodilation. 
Cardiovascular system:  
Desflurane causes peripheral vasodilatation resulting in dose-
dependent tachycardia associated with depression in myocardial 
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contractility and a decrease in systemic vascular resistance. These changes 
occur at concentrations ranging from 0.83 to 1.66 MAC. 
In ventilated patients, cardiac index remains unchanged and the 
systemic blood pressure falls. In spontaneously breathing patients, the 
cardiac index is increased. 
It is a direct coronary vasodilator and produces an overall reduction 
in cardiac work. A rapid increase in the concentration of desflurane to 
greater than 1 MAC will cause an increase in heart rate and blood 
pressure.  
Desflurane does not sensitize the myocardium to epinephrine. 
Neuromuscular effects:   
Desflurane depresses neuromuscular function. It can provide 
sufficient relaxation to allow tracheal intubation. It also potentiates the 
action of nondepolarizing muscle relaxants. 
Toxicity:  
Desflurane has low blood-gas and blood-tissue solubility and 
undergoes minimal metabolism less than 0.02 by liver. The metabolite, 
trifluoroacetic acid produced may interact with hepatic proteins and induce 
an immune response in susceptible patients.  
There is no evidence of renal toxicity, even after prolonged exposure. 
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Desflurane, under certain conditions is degraded by carbon dioxide 
absorbers, and carbon monoxide is produced. 
Desflurane is a trigger agent for malignant hyperthermia. 
Clinical uses: 
Desflurane has low blood-gas solubility and therefore provides most 
rapid induction and recovery. It undergoes minimal metabolism and the 
risk of toxicity is very low. 
SEVOFLURANE 
Sevoflurane was first synthesized in the late 1960s at Baxter-
Travenol laboratories by R F Wallin and co-workers. The first published 
recorded use in humans was in 1981. 
Physical properties: 
¾ Sevoflurane is a fluorinated methyl isopropyl ether. 
¾ It is colourless, non pungent to inhale, non-flammable and a liquid at 
room temperature. 
¾ Molecular weight: 200.5 Dalton  
¾ Boiling point: 58.5 ºC 
¾ Saturated vapour pressure: 160 mmHg 
¾ Blood-gas solubility: 0.69 
¾ Minimum alveolar concentration: 2% 
  
 
SEVOFLURANE: MOLECULAR STRUCTURE 
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Chemical structure: 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane 
Pharmacokinetics: 
Sevoflurane has a low blood-gas partition coefficient which means 
that it has a rapid induction and rapid recovery. At 30 minutes after the 
start of anesthesia, the FA/FI( fraction of alveolar to the inspired 
concentration ) for sevoflurane was 0.85 compared with 0.73 for 
isoflurane.  
Partition Coefficients of sevoflurane at 37ºC: 
Blood-Gas       : 0.69 
Brain-blood     : 1.7 
Liver-Blood    : 1.8 
Kidney-Blood : 1.2 
Muscle-Blood  : 3.1 
Fat-Blood        : 48 
The distribution of sevoflurane follows a five compartment model. 
Elimination of sevoflurane is primarily through the lungs and only a 
smaller amount is metabolised. The proportion metabolised has been 
estimated at between 1.6 % and 4.9%. Metabolism occurs in the liver, 
catalyzed by the cytochrome P450E1 enzyme. 
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Pharmacodynamics: 
Central nervous system: 
Cerebral blood flow: Sevoflurane causes cerebral vasodilatation and 
decrease in cerebral metabolic rate. Of these, vasodilatation predominates 
with a global increase in cerebral blood flow. 
Cerebral metabolic rate: There is a reduction in cerebral metabolic rate. 
Intracranial pressure: Sevoflurane causes a slight rise in the intracranial 
pressure. There is some evidence that sevoflurane has neuroexcitatory 
properties. 
The cerebrovascular response to carbon dioxide and cerebrovascular 
autoregulation are both preserved under sevoflurane anesthesia. 
Respiratory system: 
Sevoflurane is pleasant to inhale and virtually has no irritant effect 
on the airway. This, combined with its low blood-gas solubility makes it 
suitable for inhalational induction. It is a respiratory depressant, causing a 
reduction in minute ventilation. Tidal volume is reduced. The ventilatory 
response to carbon dioxide is reduced. 
Sevoflurane abolishes hypoxic pulmonary vasoconstriction in a 
dose-dependent manner in rabbit lungs. It is not proved in humans. 
Sevoflurane is an effective bronchodilator. 
29 
 
Cardiovascular system: 
Sevoflurane can produce direct myocardial depression through an 
action on calcium channels. It causes a dose dependent reduction in 
cardiac output and a reduction in systemic vascular resistance which 
results in a fall in systemic blood pressure. 
It causes a reduction in pulmonary artery pressure that is not dose 
dependent. 
Hepatic and renal blood flows are preserved. 
Sevoflurane does not sensitize the myocardium to epinephrine. It is a 
coronary vasodilator. It does not cause the sympathetic-mediated 
cardiovascular stimulation associated with rapid increases in end-tidal 
concentration. 
Neuromuscular effects: 
Sevoflurane produces dose dependent muscle relaxation. At deeper 
levels of anesthesia, it facilitates tracheal intubation. 
It potentiates the action of neuromuscular blocking agents. 
Toxicity: 
Metabolism is less significant because its tissue solubility is so low. 
Metabolism of sevoflurane results in production of inorganic fluoride and 
hexafluoroisopropanol. When sevoflurane is exposed to soda-lime or 
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baralyme, it is absorbed and degraded to a variety of compounds of which 
two are produced in significant amounts. They are fluoromethyl-2,2-
difluoro-1-(trifluoromethyl) vinyl ether ( Compound A ) and fluoromethyl-
2-methoxy-2,2-difluoro-1-(trifluoromethyl) ethyl ether ( Compound B ). 
Toxic level of fluoride to produce nephrotoxicity is greater than 
80µmol/litre. The lower the flow rate in the circle system, the higher will 
be the concentration of Compound A. The addition of water to soda-lime 
and the use of partially exhausted soda-lime seem to reduce the production 
of Compound A during low-flow anesthesia. While there is no evidence to 
date of serious long-tem renal injury associated with the use of 
sevoflurane, it would seem prudent to avoid prolonged exposure to 
sevoflurane with fresh gas flows of less than 2L/min. 
Sevoflurane is not hepatotoxic. Sevoflurane triggers malignant 
hyperthermia. 
Clinical use:  
Sevoflurane has a low blood-gas solubility, so faster induction and 
faster recovery which along with its pleasant odour, makes it an ideal 
agent for inhalational induction. Toxicity has not been proved to be a 
clinical problem even with low flows for prolonged periods.   
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AMBULATORY SURGERY 
Over the past 4 decades, ambulatory surgery has grown from less 
than 10% to over 70% of all elective surgical procedures. Ambulatory 
surgery has progressed from the practice of performing simple procedures 
on healthy outpatients to encompassing a broad spectrum of major 
procedures in outpatients with complex pre-existing medical conditions. 
The availability of rapid, shorter-acting anesthetic, analgesic, and 
muscle relaxant drugs has clearly facilitated the recovery process after 
surgery. The range of acceptable ambulatory surgical procedures continues 
to expand, and patients are presenting for outpatient surgery with 
increasingly complex medical problems. As a result, anesthesiologists 
must play a more active role in the preoperative assessment and 
preparation of these patients. The role of the anesthesiologist has evolved 
from that of a physician primarily concerned with providing optimal 
surgical conditions and minimizing pain immediately after the operation to 
that of a perioperative physician responsible for ensuring that patients with 
coexisting medical conditions are optimally managed before, during, and 
after surgery.  In modern ambulatory facilities, complex surgical 
procedures can be safely performed without sacrificing quality while 
minimizing use of hospital resources. 
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Perioperative Anesthetic Management for Facilitating a Fast-Track 
Recovery after Elective Ambulatory Surgery 
Preoperative period- the coexisting diseases should be stabilised. 
Cessation of smoking should be encouraged. The anxiety and discomfort 
should be minimised. The patients should be adequately hydrated. 
Prophylactic measures to prevent postoperative complications like nausea, 
vomiting, pain, and ileus should be used. 
Intraoperative period- Anesthetic techniques that optimize surgical 
conditions and also ensure a rapid recovery with minimal side effects 
should be used. Local analgesia via peripheral nerve blocks, wound 
infiltration, and/or instillation can be administered. Multimodal analgesia 
and antiemetic prophylaxis should be used. Avoid excessive fluid 
administration and minimise the use of nasogastric tubes and surgical 
drains. 
Postoperative period- Adequate pain control should be provided. 
The patient who meets discharge criteria should be allowed to fast-tracked. 
Early ambulation and resumption of normal activities should be 
encouraged. 
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Duration of Surgery  
The duration of surgery in the ambulatory setting was originally 
limited to procedures lasting less than 90 minutes because early 
investigators found that the operating and anesthesia times were strong 
predictors of postoperative complications (e.g., pain, emesis) and delayed 
discharge, as well as unanticipated admission to the hospital after 
ambulatory surgery. However, surgical procedures lasting 3 to 4 hours are 
now routinely performed on an ambulatory basis. Surgical procedures like 
dental extraction, facial fractures, excision of skin lesions, general surgical 
procedures, gynaecologic procedures, cataract excision, strabismus repair, 
arthroscopic procedures, closed reduction, hardware removal, 
otolaryngology procedures like adenoidectomy, laryngoscopy and 
mastoidectomy, pain clinic procedures like chemical sympathectomy, 
epidural injection and nerve blocks, plastic surgery procedures and 
urologic procedures are done under ambulatory surgery. 
Patient Characteristics: 
Originally, the majority of patients treated in ambulatory surgical 
facilities were classified as ASA physical status I or II. However, 
improved anesthesia and surgical care has allowed increasing numbers of 
medically stable ASA physical status III (and even some IV) patients to 
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undergo operations away from conventional medical centres. The risk of 
complications can be minimized if pre-existing medical conditions are 
stable for at least 3 months before the scheduled operation. Therefore, the 
ASA physical status should not be considered in isolation because the type 
of surgical procedure, the anesthetic technique, and a multitude of medical 
and social factors can also influence decisions regarding a patient's 
suitability for ambulatory surgery. 
Age:  
Age alone should not be considered a deterrent in the selection of 
patients for ambulatory surgery. Even the “elderly elderly” patient (>100 
years) should not be denied ambulatory surgery solely on the basis of age. 
Contraindications to Outpatient Surgery  
Patients with the following conditions may be at an increased risk for 
postoperative complications and should be offered the option of overnight 
hospitalization:  
• Potentially life-threatening chronic illnesses (e.g., brittle diabetes, 
unstable angina, symptomatic asthma) 
• Morbid obesity complicated by symptomatic cardio respiratory
problems (e.g., angina, asthma) 
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• Multiple chronic centrally active drug therapies (e.g., use of 
monoamine oxidase inhibitors such as pargyline and 
tranylcypromine) and/or active cocaine abuse 
• Ex-premature infants less than 60 weeks’ post conceptual age 
requiring general endotracheal anesthesia 
• No responsible adult at home to care for the patient after surgery 
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REVIEW OF LITERATURE 
1. Ravi jindal et el did a study on comparison of maintenance and 
emergence characteristics after desflurane or sevoflurane in outpatient 
anesthesia. They found that the time from administration of reversal 
agent to response to painful stimuli, to eye opening, to verbal 
commands and spontaneous eye opening were significantly shorter in 
patients administered desflurane than in patients given sevoflurane. For 
a given duration of anaesthesia, emergence from anaesthesia was 
significantly faster in desflurane compared to sevoflurane group. They 
concluded that both sevoflurane and desflurane provide a similar time 
to home readiness despite a faster wake up time with desflurane. 
2. Earl M. Strum et al compared postoperative recovery after desflurane 
versus sevoflurane anesthesia in morbidly obese adults who underwent 
gastrointestinal bypass surgery via an open laparotomy. The times from 
discontinuation of volatile anesthetic administration to eye opening, 
squeezing hand, tracheal extubation and orientation were significantly 
shorter in patients given desflurane than in patients given sevoflurane. 
They concluded that morbidly obese adult patients who underwent 
major abdominal surgery in a prospective, randomised study awoke 
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significantly faster after desflurane than after sevoflurane anesthesia 
and the patients anesthetised with desflurane had higher oxygen 
saturation on entry to the Post Anesthesia Care Unit. 
3. Wagih O. A. Ouda et al compared the emergence from anesthesia for 
day care surgery with spontaneous breathing using either desflurane or 
sevoflurane. They concluded that desflurane is associated with a faster 
emergence with no differences during the post-operative course except 
a somewhat higher incidence of airway irritation. 
4. L. La Colla et al did a study to compare desflurane vs. sevoflurane 
kinetics and dynamics in morbidly obese patients and their recovery 
profile when no premedication had been used. Patients in the desflurane 
group reported early recovery times compared with those of 
sevoflurane group. They found that the time from discontinuation of the 
anesthetic drug to eye opening after verbal command, squeezing the 
observer’s hand, extubation and ability to state their name and give 
their correct date of birth were all significantly shorter with a p value 
less than 0.001. The time from the discontinuation of the anesthetic 
drug to discharge from the recovery room was also significantly shorter 
in the desflurane group. (p<0.001). They concluded that desflurane 
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provides faster wash-in and wash-out than sevoflurane in morbidly 
obese patients, and recovery is much faster after desflurane 
administration when no premedication has been used. 
5. M H Nathanson et al compared the recovery characteristics of 
desflurane and sevoflurane when used for maintenance of ambulatory 
anesthesia. They found that there were no differences between the two 
groups in the total doses of propofol, fentanyl and vecuronium used. 
Use of desflurane led to a more rapid emergence and shorter time to 
extubation when compared to sevoflurane. Recovery of cognitive 
function and discharge times were similar in the two groups. Thus they 
concluded that it would appear that sevoflurane is an acceptable 
alternative to desflurane for maintenance of outpatient anesthesia. 
6. Rachel Eshima Mckay et al studied whether the airway reflexes return 
more rapidly after desflurane anesthesia than after sevoflurane 
anesthesia. They found that the time from stopping the anesthetic 
administration to appropriate response to command was longer in 
sevoflurane than desflurane. In addition, they found that the time from 
first response to command to ability to swallow 20ml of water without 
coughing or drooling was longer after sevoflurane. They concluded that 
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restoration of protective airway reflexes occurs significantly sooner 
after anesthesia with desflurane than after anesthesia with sevoflurane. 
7.  D Song et al did a study that was designed to test the hypothesis that 
using less soluble volatile anesthetics, desflurane and sevoflurane, as 
alternatives to propofol for maintenance of anesthesia facilitates the 
ability of outpatients to achieve postanesthesia care unit discharge 
criteria (i.e., fast-track eligibility) on arrival in the PACU after 
laparoscopic surgery. They found that compared with the propofol 
group, the times to awakening and to achieve a recovery score of 10 
were significantly shorter and the percentage of patients judged fast-
track eligible on arrival in the PACU was significantly higher, in the 
desflurane and sevoflurane groups. They concluded that, compared with 
propofol, the use of desflurane and sevoflurane for the maintenance of 
general anesthesia resulted in a higher percentage of patients being 
judged fast-track eligible after outpatient laparoscopic tubal ligation 
procedures. 
8. Paul. F. White et al compared desflurane versus sevoflurane for 
maintenance of outpatient anesthesia and the effect on early versus late 
recovery and perioperative coughing. They found that although the 
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overall incidence of coughing during the perioperative period was 
higher in the desflurane group, the incidences of coughing during the 
actual administration of the volatile anesthetics did not differ between 
the two groups. Emergence from anesthesia was more rapid after 
desflurane; however all patients achieved fast-track recovery criteria 
before leaving the operating room. Finally, the time to discharge home 
and the percentage of patients able to resume normal activities on the 
first postoperative day did not differ significantly between the two 
anesthetic groups. They concluded that the use of desflurane for 
maintenance of anesthesia was associated with a faster emergence and a 
higher incidence of coughing. They found that despite the initial earlier 
recovery with desflurane, no significant differences were found 
between the two volatile anesthetics in the late recovery profile. 
9. J Dupont et al studied the maintenance and recovery profiles after 
general anesthesia with sevoflurane, desflurane, and isoflurane in 100 
patients undergoing pulmonary surgery. The anesthetics had 
comparable hemodynamic effects and arterial oxygenation during one-
lung ventilation. They observed that emergence was twice more fast 
with desflurane than with sevoflurane or isoflurane. Early recovery was 
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also more rapid after desflurane. They concluded that in pulmonary 
surgery, desflurane, but not sevoflurane, allowed more rapid emergence 
and earlier recovery than isoflurane. 
10. Pensado Castineiras A et al compared the anesthetic maintenance 
and early postoperative recovery and psychomotor function in patients 
who have been anesthetised with desflurane, sevoflurane or isoflurane 
during prolonged open urological surgery. They found that the recovery 
times in the operating room were significantly shorter after anesthesia 
with desflurane and sevoflurane than with isoflurane, with no 
significant differences between the desflurane and sevoflurane groups. 
They concluded that desflurane and sevoflurane demonstrated 
advantages over isoflurane during recovery from anesthesia in the 
operating theatre. No significant differences were found in 
psychomotor recovery, nausea and/or vomiting or requirements for 
postoperative analgesia. 
11. Saros G B et al did a study on desflurane versus sevoflurane as the 
main inhaled anesthetic for spontaneous breathing via a laryngeal mask 
airway for varicose vein day surgery. They concluded that desflurane is 
associated with a faster emergence with no differences during the 
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postoperative course except a somewhat higher incidence of airway 
irritation. 
12. Wellborn LG et al compared the emergence and recovery 
characteristics of sevoflurane, desflurane, and halothane in paediatric
ambulatory patients. They found that emergence and recovery from 
anesthesia were significantly faster in the desflurane group compared 
with the sevoflurane and halothane groups. There was a significantly 
greater incidence of postoperative agitation and excitement in patients 
who received desflurane versus sevoflurane and halothane. There were 
no significant differences among the groups with respect to the time to 
meet home discharge criteria, in the time to drink oral fluids or in the 
incidence of postoperative vomiting. They concluded that , although 
desflurane resulted in the fastest early emergence from anesthesia, it 
was associated with a greater incidence of postoperative agitation. 
Sevoflurane resulted in similar emergence and recovery compared with 
halothane. 
13. Ira Todd Cohen, MD et al examined the effect of a single 
intraoperative dose of fentanyl on emergence characteristics after 
desflurane or sevoflurane anesthesia in children undergoing 
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adenoidectomy. They found a similar incidence of severe emergence 
agitation after general anesthesia with desflurane and sevoflurane. 
Times to achieve extubation and postanesthesia care unit discharge 
criteria were shorter with desflurane than with sevoflurane. The 
emergence was faster with desflurane than sevoflurane by 
approximately three to five minutes. They concluded that desflurane 
allows for a more rapid emergence and recovery than sevoflurane. In 
children receiving desflurane or sevoflurane, the concurrent use of 
fentanyl in a dose of 2.5µg/kg resulted in a small incidence of 
emergence agitation.  
14. Gupta A et al did a study on comparison of recovery profile after 
ambulatory anesthesia with propofol, isoflurane, sevoflurane and 
desflurane. They found no differences in early recovery between 
propofol and isoflurane. Early recovery was faster with desflurane 
compared with propofol and isoflurane and with sevoflurane compared 
with isoflurane. A minor difference was found in home readiness 
between sevoflurane and isoflurane but not among the other anesthetics. 
They concluded that comparing postoperative recovery after propofol, 
isoflurane, desflurane and sevoflurane-based anesthesia in adults 
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demonstrated the early recovery was faster in the desflurane and 
sevoflurane groups. 
15. Arain SR et al did a randomized, prospective blinded study to 
determine the emergence profiles of desflurane and sevoflurane in 
morbidly obese patients when anesthetic drug titration was used. The 
demographic variables and hemodynamic parameters were comparable 
in both the groups. Hemodynamics, time to follow commands and to 
extubation, and results of Digit Symbol Substitution Test and Mini-
Mental status Test did not differ between the anesthetic groups during 
recovery. They concluded that there were no differences in emergence 
and recovery profiles in morbidly obese patients receiving desflurane or 
sevoflurane when anesthetic concentration was carefully titrated. 
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MATERIALS AND METHODS 
After institutional ethical committee approval, the study was 
conducted in 60 patients. All were ASA I and II patients undergoing 
elective surgical procedures under general anesthesia lasting for less than 3 
hours but more than 1 hour duration. After getting consent, the anesthetic 
technique was performed. 
SELECTION OF PATIENTS: 
  The patients selected for this study were of ASA Risk I&II 
undergoing elective surgical procedures under general anesthesia lasting 
for less than 3 hours but more than 1 hour duration. It was a prospective 
randomized controlled single blinded study.The patients exhibiting the 
following were excluded from the study. 
- Significant cardiovascular, respiratory, hepatic, renal, neurologic, 
psychiatric or metabolic disease. 
- Recent anesthetic exposure within previous seven days. 
- History of allergic reaction to drugs. 
- Potential susceptibility to malignant hyperthermia. 
- Patient on chronic opioid analgesic or sedative treatment. 
Age group: 
  Age of the patients ranged from 18 to 60 years. 
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PREOPERATIVE PREPARATION: 
        In the preoperative examination, all the patients were asked for any 
history of systemic illness like hypertension, diabetes, seizure disorder, 
bronchial asthma. History of any muscular dystrophies, neuromuscular 
disorders and family history of any malignant hyperthermia were noted. 
History of any allergic reactions to drugs and any chronic drug intake were 
noted. History of any previous surgeries was noted. Examination of the 
cardiovascular system and respiratory system were done. Assessment of 
the airway and the range of neck movements were done to rule out any 
difficult intubation. Apart from the routine blood investigations like 
haemoglobin, blood sugar, blood urea and serum creatinine, 
electrocardiogram and chest x-ray were ordered in patients greater than 40 
years of age.  
Hypertensive patients were advised to continue the antihypertensives 
on the day of surgery. Diabetic patients were advised to skip the morning 
dose of insulin. The surgeons were instructed to post the diabetic case first 
in the list and to send the patient to the operating room with the fasting 
blood sugar and urine acetone values taken on the day of surgery. 
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On arrival to the preoperative room, all patients were premedicated 
with injection midazolam 0.05mg/kg and injection glycopyrrolate 10µg/kg 
intravenously 30minutes prior to induction. 
The patients were randomly allocated into two groups: 
  GROUP S- Sevoflurane 30 patients 
  GROUP D-Desflurane 30 patients 
PROCEDURE DETAILS: 
        After shifting the patient inside the operating room, pre induction 
monitors pulseoximetry, non invasive blood pressure and 
electrocardiogram were connected. After securing the intravenous line and 
starting a crystalloid solution, all patients were induced with injection 
thiopentone sodium 5mg/kg, injection fentanyl 2µg/kg and intubated with 
injection succinylcholine 1.5mg/kg. After intubation capnography was 
connected. Group D was maintained with 3% desflurane and group S with 
1% sevoflurane in 50% oxygen with 50% nitrous oxide. Neuromuscular 
blockade was maintained with injection vecuronium, initial bolus dose of 
0.1mg/kg was given. Ventilation was controlled to maintain end-tidal 
carbon dioxide between 35and40mmhg. Injection fentanyl 0.5µg/kg was 
repeated every 30 minutes. Injection vecuronium 0.02mg/kg was repeated 
every 30 minutes. Mean arterial pressure and heart rate were noted before 
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induction and every 5minutes after induction. If there is any increase in the 
mean arterial pressure and heart rate more than 20% of the preinduction 
values, an additional dose of injection fentanyl 1µg/kg was given to 
maintain the hemodynamics. If there is any reduction in the mean arterial 
pressure more than 20% from the baseline value, it was treated with bolus 
of intravenous fluids and replacement of intraoperative blood loss. When 
the hemodynamics of the patient was unresponsive to the above measures, 
the patient was excluded from the study. Nitrous oxide and volatile 
anesthetic were discontinued after the last skin suture. Residual 
neuromuscular blockade was reversed with injection neostigmine 40µg/kg 
and injection glycopyrrolate 10µg/kg intravenously. Trachea was 
extubated when regular spontaneous breathing pattern was re-established 
and when the patients were able to open their eyes on command. 
The time of discontinuation of anesthetic agents were noted as time 
zero for all the subsequent measurements and recovery times were 
determined at 1-minute intervals to awakening. 
PARAMETERS OBSERVED: 
¾ Number of additional doses of fentanyl needed. 
¾ TIME TO-  1. First spontaneous motion 
                           2. Response to painful pinch 
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                           3. Extubation 
                           4. Recall of name 
                           5. Hand grip  
                           6. Achieve a PARS > 10 (post anesthesia recovery score 
of Aldrete and Kroulik) 
This PARS records vital signs with patients receiving 0-18 points, 
that is 0-3 points for five physiological variables. One designated 
investigator administered all anesthesia; another assessed recovery. 
    PARAMETERS                        SCORE 
Consciousness 
Easily arousable, alert   3 
Arousable, oriented, not alert          2 
  Arousable, not oriented                    1 
  Not responding                                0 
Ventilation 
   Normal                                   2 
    Not perfect, but requires no support 1 
   Airway requires support          0 
Circulation (mean, supine, sitting ) 
  Arterial pressure difference 
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        < 10 %                                         2 
10-20                                  1  
 >20 %                                    0 
Horizontal nystagmus 
Follow command, no nystagmus    2 
  Follow command, nystagmus         1 
Fail to follow command              0 
Countdown test ( backward from 10 to 0 ) 
Succeed right away                    2 
Succeed in 30 seconds                1 
Fail in 30 seconds                      0 
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STATISTICAL TOOLS 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-
square  test was used to test the significance of difference between 
quantitative variables and Yate’s chi square test for qualitative variables. A 
'p' value less than 0.05 is taken to denote significant relationship.  
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OBSERVATIONS AND RESULTS 
Table 1: Age distribution 
Age group 
Desflurane 
group 
Sevoflurane 
group 
No % No % 
Up to 20 years 1 3.3 1 3.3 
21-30 years 6 20 5 16.7 
31-40 years 8 26.7 11 36.7 
41-50 years 10 33.3 8 26.7 
Above 50 years 5 16.7 5 16.7 
Total 30 100 30 100 
Range 19-57 years 20-60 years 
Mean 39.8 years 39.4 years 
SD 10.8 years 10.4 years 
‘p’ 
0.7729 
Not significant 
 
 Cases studied in the desflurane group had an age of 39.8 +10.8 years 
and the sevoflurane group had an age of 39.4+ 10.4 years. There was no 
statistically significant difference. 
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Table 2: Sex distribution 
 
Sex 
Desflurane 
 group 
Sevoflurane 
group 
No % No % 
Male 16 53.3 16 53.3 
Female 14 46.7 14 46.7 
Total 30 100 30 100 
‘p’ 1.0 Not significant 
 
 The sex composition of the two groups was identical without any 
difference. 
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PROFILE OF CASES STUDIED 
Table 3: Diagnosis 
Cases 
Desflurane group Sevoflurane group 
No % No % 
Carcinoma breast 6 20 4 13.3 
Cholelithiasis 4 13.3 8 26.7 
Epigastric hernia 3 10 3 10 
Multi nodular goitre 
Thyroid 3 10 4 13.3 
Gynaecomastia 4 13.3 5 16.7 
Solitary nodular goitre 
Thyroid 3 10 1 3.3 
Others 
Bilateral cervical adenitis 
Bilateral fibroadenoma 
Bilateral gynaecomastia 
Bilateral inguinal hernia 
Fibroadenoma 
Incisional hernia 
Pain abdomen for 
evaluation 
Right iliac fossa mass 
Umbilical hernia 
7 
- 
1 
1 
- 
1 
1 
1 
1 
1 
23.3 
- 
3.3 
3.3 
- 
3.3 
3.3 
3.3 
3.3 
3.3 
5 
1 
- 
- 
1 
1 
1 
- 
1 
- 
16.7 
3.3 
- 
- 
3.3 
3.3 
3.3 
- 
3.3 
- 
Total 30 100 30 100 
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Table 4: ASA status 
ASA Status 
Desflurane group
Sevoflurane 
group 
No % No % 
1 16 53.3 17 56.7 
2 14 46.7 13 43.3 
Total 30 100 30 100 
‘p’ 
0.7969 
Not significant 
 
There was no significant difference in the ASA status of the two groups.         
(‘p’ > 0.05) 
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Table 5: Weight 
 
Parameter 
Weight(in kgs) 
Desflurane Group Sevoflurane group 
Range 48 – 58 46 – 58 
Mean 52.5 52.2 
SD 3.0 3.1 
‘p’ 
0.7125  
Not Significant 
 
The weight of the patients was comparable in both the groups. 
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Table 6: Duration of surgery 
 
Parameter 
Duration of surgery (in minutes) 
Desflurane Group 
Sevoflurane 
group 
Range 80 – 150 80 – 150 
Mean 112 110.2 
SD 19.4 18.4 
‘p’ 
0.5131 
Not Significant 
 
There was no statistically significant difference between the two 
groups in terms of duration of surgery. 
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Table 7: Number of additional doses of fentanyl 
 
Parameter 
Number of additional doses of 
fentanyl 
Desflurane 
Group 
Sevoflurane 
group 
Range 0 – 3 0 – 2 
Mean 1.47 0.33 
SD 0.9 0.55 
‘p’ 
0.0001 
Significant 
 
The number of additional doses of fentanyl needed in desflurane 
group was 1.47 and in sevoflurane group was 0.33. This difference was 
statistically significant with a p value of 0.0001. 
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B: Efficacy of the two drugs 
Table 8: Time to spontaneous motion 
Parameter 
Time to spontaneous motion 
( in minutes) 
Desflurane 
Group 
Sevoflurane group 
Range 3 – 5 6 – 9 
Mean 4 7.2 
SD 0.69 0.76 
‘p’ 
0.0001 
Significant 
 
 Time to spontaneous motion in the desflurane group was 4.0 +0.69 
minutes whereas it was 7.2+0.76 minutes in the sevoflurane group. This 
difference was statistically significant (p = 0.0001). 
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Table 9: Time to response to pain 
 
Parameter 
Time to response to pain 
(in minutes) 
Desflurane 
Group 
Sevoflurane 
group 
Range 4 – 7 7 - 11 
Mean 5.37 8.57 
SD 0.85 0.86 
‘p’ 
0.0001 
Significant 
 
 Time to response to pain in the sevoflurane group (8.57 +0.86 
minutes) was significantly (p = 0.0001) higher than that in the desflurane 
group (5.37 +0.85 minutes). This difference was statistically significant. 
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Table 10: Time to extubation 
 
Parameter 
Time to extubation 
(in minutes) 
Desflurane 
Group 
Sevoflurane 
group 
Range 5 – 8 8 - 12 
Mean 6.53 10.4 
SD 0.82 1.07 
‘p’ 
0.0001 
Significant 
 
 Time to extubation in desflurane group was 6.53minutes when 
compared to sevoflurane group of 10.4minutes. This difference in the 
mean time to extubation was statistically significant. 
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Table 11: Time to recall of name 
 
 
 
Time to recall of name 
(in minutes) 
Desflurane 
Group 
Sevoflurane 
group 
Range 6 – 9 10 – 14 
Mean 7.83 12.33 
SD 0.79 1.21 
‘p’ 
0.0001 
Significant 
 
 Patients in the desflurane group were able to recall their name in 
7.83 +0.79 minutes. But those in the sevoflurane group were able to recall 
their name only after 12.33 +1.21 minutes. This difference was statistically 
significant  (p = 0.0001). 
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Table 12: Time to hand grip 
 
Parameter 
Time to hand grip 
(in minutes) 
Desflurane 
Group 
Sevoflurane 
group 
Range 8 – 11 12 – 17 
Mean 9.37 14.27 
SD 0.89 1.34 
‘p’ 
0.0001 
Significant 
 
 Time to hand grip in desflurane group was 9.37 +0.89 minutes and 
in sevoflurane group was 14.27 +1.34 minutes. There existed statistically 
significant difference between the two groups. (‘p’=0.0001) 
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Table 13: Time to achieve PARS > 10 
 
Parameter 
Time to achieve PARS > 10 
(in minutes) 
Desflurane Group 
Sevoflurane 
group 
Range 9 – 12 14 -  19 
Mean 10.47 16.63 
SD 0.86 1.47 
‘p’ 
0.0001 
Significant 
 
 Patients in the desflurane group achieved PARS > 10 at 10.47 +0.86 
minutes whereas the patients in the sevoflurane group were able to achieve 
it only after 16.63 +1.47 minutes. This difference was statistically 
significant (p < 0.05). 
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Table 16:  Changes in Pulse Rate 
 
 
Variable 
  
‘p’ Desflurane 
Group 
Sevoflurane 
group 
Baseline Pulse 
Rate 
82.7 +  7.7 84.2 +  8.2 
0.4092 
Not significant 
Intra operative 
Pulse Rate 
82.7 +  7.2 80.1 +  8.1 
0.2704 
Not significant 
 
Baseline pulse rate and intraoperative pulse rate were comparable 
between the desflurane and sevoflurane groups. There was no statistically 
significant difference. 
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Table 17:  Changes in Mean Arterial Pressure 
 
Variable 
Changes in Mean Arterial Pressure 
mmHg ‘p’ 
Desflurane Group Sevoflurane group 
Baseline Mean 
Arterial 
Pressure 
64.7 +  3.2 65.3 +  3 
0.4097 
Not 
significant 
Intra operative 
Mean Arterial 
Pressure 
65.11 +  3.27 63.69+  2.96 
0.06849 
Not 
significant 
 
The baseline and intraoperative mean arterial pressure in both 
desflurane and sevoflurane groups were comparable with no statistically 
significant difference. 
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DISCUSSION 
General anesthesia is popular among the surgeons, 
anaesthesiologists, and patients and still remains the mainstay of 
anesthesia in many centres. With the introduction of less soluble volatile 
anesthetics which promote early recovery and also maintains 
hemodynamics and provide amnesia makes general anesthesia the 
technique of choice for many patients. 
It is desirable to have a faster recovery from anesthesia. This study 
compared the hemodynamic, emergence and recovery characteristics of 
sevoflurane with desflurane in general anesthesia. 
The time to spontaneous motion, eye opening, response to pain were 
shorter in the desflurane group. The time to extubation, recall of name, and 
hand grip were also shorter in the desflurane group compared to 
sevoflurane group. Post anesthesia recovery score of greater than 10 was 
achieved earlier in the desflurane group.  
In the desflurane group, patient moved their limbs in a mean time of 
4minutes after the discontinuation of the anesthetics whereas it took a 
mean of 7.2minutes in the sevoflurane group. 
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The time to response to pain was achieved in a mean time of 
5.37minutes in the desflurane group whereas in the sevoflurane group it 
took a mean of 8.57minutes. 
              The patients in the desflurane group were extubated earlier than 
those in the sevoflurane group. The patients in the desflurane group were 
able to recall their names in a mean time of 7.83minutes whereas those in 
the sevoflurane group took 12.33minutes. 
             The time to hand grip was achieved earlier in the desflurane group.  
The post anesthesia recovery score of greater than 10 (PARS>10) was 
achieved in a mean of 10.47minutes in desflurane group which was earlier 
than sevoflurane. 
The study by Nathanson et al. suggested that sevoflurane and 
desflurane provided similar intraoperative conditions during the 
maintenance period. Although early recovery was more rapid after 
desflurane, there was no difference in later recovery end-points. 
  Randomised, double-blind study of Tarazi et al. showed that both 
sevoflurane and desflurane were acceptable inhalational anaesthetics for 
outpatient tubal ligation surgery. 
In this study there was no significant difference in the recovery times 
between the two groups after 30minutes. 
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Song et al. found that the late recovery profiles and incidences of 
postoperative side effects were similar after desflurane and sevoflurane. It 
was also showed that regardless of the duration of anaesthesia, elimination 
was faster and recovery was quicker for the inhaled anaesthetic desflurane 
than for the inhaled anaesthetic sevoflurane.   
Hemodynamic profile 
Both the desflurane and sevoflurane maintained the hemodynamics 
within 20% of the baseline values, but desflurane required more number of 
additional doses of fentanyl than sevoflurane. 
In the desflurane group, hemodynamics could not be maintained 
with the additional doses of fentanyl in 3 patients and they were excluded 
from the study, were as in the sevoflurane group, only 1 patient was 
excluded from the study. 
Hypotension was easily managed with fluids and blood replacement 
and none of the patients were excluded in both the groups. 
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SUMMARY 
The aim of this study is to prospectively compare the hemodynamic, 
emergence and recovery characteristics of sevoflurane with that of 
desflurane in general anesthesia. 60 ASA I and II patients undergoing 
elective surgical procedures less than 3 hours duration under endotracheal 
general anesthesia were randomly divided into two groups. Both the 
groups were induced with standard intravenous induction technique. 
Group D was maintained with 3% desflurane and group S with 1% 
sevoflurane in 50% oxygen with 50% nitrous oxide. Injection fentanyl 
0.5µg/kg was repeated every 30 minutes. Injection vecuronium 0.02mg/kg 
was repeated every 30 minutes. Mean arterial pressure and heart rate were 
noted before induction and every 5 minutes after induction.   If there is any 
increase in the mean arterial pressure and heart rate more than 20% of the 
preinduction values, an additional dose of injection fentanyl 1µg/kg was 
given. If there is any reduction in the mean arterial pressure more than 
20% from the baseline value, it was treated with bolus of intravenous 
fluids and replacement of intraoperative blood loss. When the 
hemodynamics of the patient was unresponsive to the above measures, the 
patient was excluded from the study. Nitrous oxide and volatile anesthetic 
were discontinued after the last skin suture. Residual neuromuscular 
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blockade was reversed with injection neostigmine 40µg/kg and injection 
glycopyrrolate 10µg/kg intravenously. The following were noted and 
recorded. 
The time of discontinuation of anesthetic agents were noted as time 
zero for all the subsequent measurements and recovery times were 
determined at 1-minute intervals to awakening. 
Number of additional doses of fentanyl needed was noted. 
Time to – 1. First spontaneous motion 
                  2. Response to painful pinch 
                  3. Extubation 
                  4. Recall of name 
                  5. Hand grip 
                  6. Achieve a PARS> 10 (post anesthesia recovery score of 
Aldrete and Kroulik) were noted. 
The following results were obtained. Of the two groups compared, 
1. Age, sex, weight and the duration of surgery were comparable in both 
the groups. 
2. Both desflurane and sevoflurane maintained hemodynamics, but 
desflurane needed more number of additional doses of fentanyl to 
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maintain the hemodynamic stability. This difference was found to be 
statistically significant. 
3. The time to first spontaneous motion, response to pain, extubation, 
recall of name, and hand grip were shorter in the desflurane group 
than the sevoflurane group. The difference was statistically 
significant. 
4. The time to achieve a PARS of greater than 10 was earlier in the 
desflurane group and it was statistically significant. 
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CONCLUSION 
In conclusion, desflurane provides earlier emergence and recovery 
from anesthesia compared to sevoflurane. Both desflurane and 
sevoflurane maintained hemodynamic stability, but to maintain the 
hemodynamics desflurane needed more number of additional doses of 
fentanyl. 
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PROFORMA 
COMPARISON OF HEMODYNAMIC, EMERGENCE AND 
RECOVERY CHARACTERISTICS OF SEVOFLURANE WITH 
DESFLURANE 
NAME:       AGE:        IPNO: 
DIAGNOSIS:      PROCEDURE: 
ASA:      I / II                                                            WEIGHT: 
DURATION OF THE SURGERY: 
PREMEDICATION: Inj.midazolam 0.05mg/kg IV 
                                   Inj.glycopyrollate 10µg/kg IV 
PREOPERATIVE: Mean arterial blood pressure: 
                                Pulse rate: 
GENERAL ANESTHESIA: Induction: Inj.thiopentone 5mg/kg 
                                                                Inj.fentanyl 2µg/kg 
                                                                Inj.succinylcholine 1.5mg/kg 
Injection fentanyl 0.5µg/kg repeated every 30mins after induction. 
Neuromuscular blockade maintained with injection vecuronium 0.1mg/kg bolus 
dose followed by 0.02mg/kg every 30minutes. 
 
 GROUP:   DESFLURANE/SEVOFLURANE 
 DESFLURANE GROUP: 3% desflurane in 50% oxygen and 50% nitrous 
oxide. 
SEVOFLURANE GROUP: 1% sevoflurane in 50% oxygen and 50% nitrous 
oxide. 
 
If there is any increase in the mean arterial pressure  and heart rate more 
than 20% of the preinduction values, a rescue dose of injection fentanyl 1µg/kg 
was given. 
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Time Mean arterial pressure Heart rate 
Pre-induction   
5minutes   
10minutes   
15minutes   
20minutes   
25minutes   
30minutes   
35minutes   
40minutes   
45minutes   
50minutes   
55minutes   
60minutes   
   
   
 
 
Parameters observed: 
 
Number of rescue doses of fentanyl needed: 
 
Parameter- Time to Time in minutes 
First spontaneous motion  
Response to painful pinch  
Extubation  
Recall of name  
Hand grip  
Achieve a PARS > 10.  
 
Sl.
No.
age sex weight ip no asa status
blood
sugar
 blood
urea
 serum
creatinine
serum 
sodium
serum 
potassium
1 19 m 56 6405 1 72 24 0.9 134 3.5
2 28 f 52 7710 1 78 20 0.8 136 3.3
3 50 m 50 2270 1 76 28 0.7 142 4.1
4 37 f 54 5587 2 88 26 1 137 3.6
5 28 f 48 5917 2 102 30 0.9 143 3.7
6 57 f 51 5932 1 112 30 0.8 138 3.8
7 41 m 56 8946 1 96 28 1.2 134 3.6
8 54 m 48 5629 2 92 22 0.8 135 3.5
9 24 f 48 5876 1 100 24 0.9 136 3.6
10 45 f 50 6453 1 86 28 0.9 135 3.3
11 38 f 52 6618 2 108 22 0.8 133 3.8
12 47 m 56 7153 2 104 20 0.9 136 4
13 50 f 52 6827 2 68 22 0.9 135 4.2
14 52 f 50 5613 2 72 24 0.7 136 3.7
15 34 m 56 7324 1 78 32 0.9 137 3.8
16 56 m 50 5647 2 88 28 0.8 142 3.5
17 32 m 58 6702 1 118 34 1.2 141 3.6
18 45 m 52 6134 1 112 30 0.9 142 3.7
19 38 f 48 6713 1 108 22 0.8 136 3.6
20 25 f 50 7215 1 110 26 0.9 137 3.8
21 45 f 52 6317 2 98 22 0.8 136 3.7
22 23 m 54 5438 2 94 32 1.2 135 3.6
23 40 f 50 4876 1 98 34 1 133 3.5
24 32 m 54 6721 2 76 22 0.8 134 3.3
25 53 m 56 5317 2 78 24 0.9 137 3.5
26 36 m 58 4637 2 86 22 0.8 135 3.7
27 27 m 54 5134 1 88 24 0.7 138 3.8
28 43 f 52 6120 2 78 22 0.8 136 3.6
29 50 m 54 6112 1 95 24 0.9 135 3.5
30 32 m 54 6218 1 92 20 0.7 134 3.5
epigastric hernia
mng thyroid
cholelithiasis
ca breast
umbilical hernia
meena
ca breast
gynaecomastia
mng thyroid
parimala
petchi
ca breast
rif mass
ca breast
ca breast
gynaecomastia
cholelithiasis
mng thyroid
cholelithiasis
sng thyroid
epigastric hernia
ca breast
b/l fibroadenoma
gynaecomastia
cholelithiasis
sng thyroid
mani
maruthu
rajan
ashok
rani
kulandaivelu
mari
surya
chitra
kaliammal
poongodi
bagyam
kannan
muthu
murugan
palani
Name diagnosis
incisional hernia
pain abdomen
mani
muthu
raja
murugeswari
ayyanar
bose
thangam
subash
banu
amirtha
sng thyroid
fibroadenoma
epigastric herniamuthukumar
b/l gynaecomastia
gynaecomastia
GROUP ‐ D (Desflurane Group)
baseline
PR
baseline
MAP
intraop
PR
intraop
MAP 
No.of 
Additional 
doses of 
Fentanyl
duration 
of Surgery
time to 
spontaneous 
motion
time to
response 
to pain
time to 
extubation
time to
 recall of 
name
time to
 hand grip
time to 
achieve 
PARS>10
76 66 74.6 63.3 1 120mins 4 5 8 9 11 11
72 64 72.8 66 2 95mins 3 5 6 7 9 10
78 58 76.6 58 nil 100mins 4 4 7 8 10 12
82 66 80.8 64.2 1 90mins 4 6 7 8 11 11
84 62 82.2 64.8 2 120mins 5 7 8 9 11 12
86 68 84.4 66 1 140mins 5 5 6 8 9 10
88 70 86.2 70.2 nil 100mins 5 7 7 8 9 11
72 68 72.6 70.8 3 120mins 3 4 5 7 8 9
76 66 76.4 66.6 1 100mins 4 5 8 9 11 11
74 64 74.2 64.8 1 95mins 4 4 5 6 8 9
92 62 80.8 60.2 nil 100mins 4 6 7 8 9 10
90 58 88.6 60.4 1 150mins 5 7 8 9 10 11
94 66 90.8 64.6 nil 120mins 4 5 6 8 9 11
96 60 92.8 60.2 1 120mins 4 6 7 8 9 11
88 64 86.8 65.3 1 100mins 4 5 6 8 9 11
72 62 76.4 60 2 120mins 5 6 7 9 10 12
76 66 74.6 64.6 1 110mins 3 5 6 8 9 10
72 62 76.4 64 3 110mins 4 5 7 8 10 11
76 62 78.2 64.3 3 120mins 4 6 6 7 9 10
74 64 70.8 64.6 2 140mins 5 6 7 9 10 11
82 66 82.8 66.8 2 150mins 3 4 6 7 8 9
84 68 84.2 68.2 1 110mins 4 5 6 8 9 10
84 70 88.6 68 3 90mins 4 6 7 8 10 11
88 70 88.8 72.4 2 110mins 4 5 6 7 9 10
92 66 94.6 66.4 2 120mins 3 5 6 8 9 10
80 62 82.4 64.3 2 120mins 3 5 6 7 8 9
92 68 92.2 68.2 1 110mins 5 6 7 8 10 11
96 66 96.2 68 1 110mins 4 6 6 7 9 10
84 64 88.6 62 2 90mins 3 5 6 7 9 10
82 64 84.4 66.2 2 80mins 4 5 6 7 9 10
GROUP ‐ D (Desflurane Group)
Sl.
No.
age sex weight ip no asa status
blood
sugar
 blood
urea
 serum
creatinine
serum 
sodium
serum 
potassium
1 20 m 54 5481 2 76 22 0.8 135 3.6
2 32 m 52 6233 2 80 28 0.8 134 3.5
3 49 m 56 5601 1 88 24 0.9 133 3.5
4 38 f 50 6108 1 86 26 0.7 136 4.2
5 30 f 48 7324 1 96 30 1 137 3.9
6 60 f 46 7642 2 98 34 0.9 138 3.3
7 40 m 50 6435 1 92 26 0.9 142 3.5
8 52 m 50 8120 2 88 28 0.9 144 3.6
9 25 m 56 5430 1 72 28 0.8 134 3.7
10 36 f 50 7120 1 76 30 0.7 136 3.4
11 33 f 52 6091 1 78 30 1 135 3.3
12 45 f 52 5640 1 86 34 8 137 3.5
13 36 f 48 8012 2 72 20 0.9 138 3.5
14 49 m 56 5098 1 88 28 1 135 3.6
15 51 f 50 6420 2 92 27 1.1 136 3.7
16 53 f 52 7320 2 98 24 1 137 3.8
17 34 m 56 8006 2 112 32 0.9 138 3.8
18 55 m 54 6408 1 102 30 0.8 133 3.7
19 44 m 52 7054 1 98 20 0.8 134 3.6
20 46 m 58 7508 2 112 20 0.7 135 3.6
21 36 f 52 6987 1 118 28 0.9 136 3.5
22 25 f 48 8240 2 104 26 0.8 137 3.5
23 43 f 50 6726 2 108 24 0.9 138 3.3
24 23 m 56 5480 1 76 22 0.7 139 3.7
25 39 f 50 6087 2 68 32 0.7 134 3.6
26 31 m 54 5624 1 70 32 0.8 134 4.2
27 50 m 54 7410 2 92 34 0.9 136 4.1
28 36 m 52 5241 1 90 20 0.9 134 3.5
29 27 m 58 5439 1 100 24 1 133 3.5
30 43 f 50 6552 1 102 22 1 137 3.6
diagnosis
GROUP ‐ S (SEVOFLURANE GROUP)
kannan
pankajam
karpagam
kailash
kamala
manikandan
sundar
periyanan
madhan
karuppu
kani
aruna
vasuki
durai
malliga
jeya
keasavan
sng thyroid
incisional hernia
cholelithiasis
karupayee
subbiah
mookan
paneer
asairaj
thavamani
meena
pavithra
Name
pandi
paulraj epigatric hernia
cholelithiasis
gynaecomastia
cholelithiasis
arumugam
mari
muthu
gynaecomastia
mng thyroid
ca breast
ca breast
b/l inguinal hernia
gynaecomastia
mng thyroid
ca breast
cholelithiasis
cholelithiasis
rif mass
ca breast
gynaecomastia
gynaecomastia
epigatric hernia
cholelithiasis
mng thyroid
cholelithiasis
epigatric hernia
cholelithiasis
mng thyroid
fibroadenoma
b/l cervical adenitis
baseline
PR
baseline
MAP
intraop
PR
intraop
MAP 
No.of 
Additional 
doses of 
Fentanyl
duration 
of Surgery
time to 
spontaneous 
motion
time to
response 
to pain
time to 
extubation
time to
 recall of 
name
time to
 hand grip
time to 
achieve 
PARS>10
76 64 72.2 64 1 110mins 6 8 10 11 13 14
72 66 68.8 64 nil 90mins 7 8 11 13 14 16
74 68 72.2 68.3 nil 100mins 6 7 8 10 12 14
78 66 76.8 64.2 nil 100mins 7 8 10 11 13 15
84 64 82.4 62 1 90mins 6 7 9 10 12 14
88 58 88.2 56.6 nil 110mins 8 9 10 11 13 16
68 66 60.6 68.2 nil 120mins 7 8 10 12 14 16
90 64 84.6 60.8 nil 150mins 7 8 10 13 15 17
92 68 90.2 66 2 90mins 7 9 10 12 14 16
94 66 88.6 64.3 nil 100mins 7 9 11 12 14 16
96 70 88.8 67 nil 110mins 6 8 9 11 13 15
88 66 84.2 63.6 nil 120mins 8 9 11 14 16 18
84 58 80.6 58.8 nil 140mins 6 7 8 10 12 14
72 70 68.6 68.6 nil 110mins 7 9 10 12 14 17
76 66 68.8 65 1 95mins 7 9 12 13 15 17
76 64 70.2 63.3 nil 110mins 8 9 11 13 14 17
72 70 70.2 68.4 nil 100mins 8 9 11 13 15 18
78 66 72.6 64 1 120mins 8 11 12 14 17 19
88 68 84.2 65.4 1 140mins 7 8 10 13 15 18
90 64 86.8 62.3 nil 80mins 8 9 11 14 16 19
92 62 88.2 60 1 90mins 7 8 10 12 13 16
96 66 88.8 64 nil 110mins 7 9 11 13 15 17
84 68 80.2 66 nil 100mins 7 8 10 12 14 17
84 62 80.2 60.2 nil 120mins 8 9 12 14 17 19
92 64 86.8 62.2 nil 140mins 7 9 10 12 14 17
84 66 80.8 63.9 1 150mins 7 9 12 13 15 17
88 68 82.6 66 nil 100mins 8 9 11 13 14 17
84 64 78.8 60.8 nil 110mins 7 8 10 12 14 17
90 62 86.8 60.8 1 100mins 9 10 12 14 16 18
96 66 88.8 62 nil 100mins 8 9 11 13 15 18
GROUP ‐ S (SEVOFLURANE GROUP)
COMPARISON OF HEMODYNAMIC, EMERGENCE AND 
RECOVERY CHARACTERISTICS OF SEVOFLURANE 
WITH DESFLURANE IN GENERAL ANESTHESIA. 
Abstract: 
Background:  
Inhaled volatile anaesthetics remain the most widely used drugs for 
maintenance of general anaesthesia because of their ease of administration 
and predictable intraoperative and recovery characteristics. Management 
of hemodynamic stability and early recovery is the most important part of 
a standardized balanced technique. Given the low blood-gas partition 
coefficients of sevoflurane (0.69) and desflurane (0.42), a more rapid 
emergence from anaesthesia is expected compared with traditional 
inhalation anaesthetics. This study was undertaken with the aim of 
prospectively comparing the hemodynamic, emergence and recovery 
characteristics of sevoflurane with desflurane in general anesthesia. 
Methods:  
Sixty ASA I and II patients undergoing elective surgical procedures 
under endotracheal general anesthesia were randomly assigned to receive 
either sevoflurane 1% or desflurane 3% for maintenance of general 
anesthesia after standardised intravenous induction sequence. 
Measurement of hemodynamics was done before induction and every 
5minutes after induction. During the intraoperative period, if mean arterial 
pressure increases above 20% of preinduction value, an additional dose of 
fentanyl was given. Hypotension was treated with intravenous fluids and 
replacement of blood loss. The number of additional doses of fentanyl 
required was noted. The time of discontinuation of the inhaled anesthetics 
to spontaneous movement, response to painful stimuli, extubation, recall 
of name, handgrip and to achieve a post anesthesia recovery score of 
greater than 10 were measured. 
Results:   
 Both the groups were comparable in terms of age, sex, weight and 
duration of surgery. The number of additional doses of fentanyl required 
was more in the desflurane group, (p<0.0001). The time to spontaneous 
movement, response to painful stimuli, extubation, recall of name and 
handgrip were shorter in the desflurane group, (p<0.0001). The time to 
achieve recovery score of greater than 10 was shorter in desflurane group 
with a p value < 0.0001. 
 
 
Conclusion: 
 In conclusion, desflurane provides earlier emergence and recovery 
from anesthesia compared to sevoflurane. Both desflurane and sevoflurane 
maintained hemodynamic stability, but to maintain the hemodynamics 
desflurane needed more number of additional doses of fentanyl.    
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